TScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest Update

TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) was the recipient of a large decline in short interest in January. As of January 15th, there was short interest totalling 2,000,000 shares, a decline of 20.6% from the December 31st total of 2,520,000 shares. Currently, 4.6% of the shares of the stock are short sold. Based on an average trading volume of 403,800 shares, the short-interest ratio is presently 5.0 days.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on TCRX shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 price objective on shares of TScan Therapeutics in a report on Wednesday, December 11th. Wedbush reissued an "outperform" rating and set a $7.00 price target on shares of TScan Therapeutics in a report on Monday, December 23rd. Finally, HC Wainwright reissued a "buy" rating and set a $15.00 price target on shares of TScan Therapeutics in a report on Wednesday, December 11th.

TScan Therapeutics Price Performance

TCRX traded up $0.04 on Wednesday, reaching $2.47. The stock had a trading volume of 72,853 shares, compared to its average volume of 283,401. TScan Therapeutics has a fifty-two week low of $2.31 and a fifty-two week high of $9.69. The firm has a 50-day moving average of $3.12 and a 200-day moving average of $4.69. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $131.56 million, a price-to-earnings ratio of -2.33 and a beta of 0.88.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.03. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The business had revenue of $1.05 million during the quarter, compared to analysts' expectations of $2.86 million. As a group, sell-side analysts anticipate that TScan Therapeutics will post -1.12 EPS for the current year.

Hedge Funds Weigh In On TScan Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of Montreal Can bought a new stake in shares of TScan Therapeutics in the 2nd quarter valued at about $749,000. State Street Corp grew its position in shares of TScan Therapeutics by 24.4% in the 3rd quarter. State Street Corp now owns 756,499 shares of the company's stock valued at $3,767,000 after buying an additional 148,414 shares during the last quarter. Geode Capital Management LLC grew its position in shares of TScan Therapeutics by 8.1% in the 3rd quarter. Geode Capital Management LLC now owns 973,466 shares of the company's stock valued at $4,849,000 after buying an additional 72,967 shares during the last quarter. Stifel Financial Corp boosted its position in shares of TScan Therapeutics by 3.9% during the 3rd quarter. Stifel Financial Corp now owns 99,133 shares of the company's stock valued at $494,000 after purchasing an additional 3,733 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of TScan Therapeutics during the 3rd quarter valued at about $112,000. Institutional investors and hedge funds own 82.83% of the company's stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.